Mannkind expects Q4 revenue of about $38 million, plus or minus. Natetanib DPI moves toward Phase 2 in the U.S. after FDA feedback.
MNKD · Mannkind Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $3.95
- Open
- $4.07
- Day range
- $3.89–4.08
- 52-week closing range
- $2.28–6.21
- Average volume, 30 days
- 3.5M
- Short interest
- 26.2M · 8.2% of shares · 10.3 days
- Short volume, last session
- 38%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Mankind Corporation reported third-quarter revenue of $101.9 million, up 24%, while roughly 75% of Furosix shipments had moved to ReadyFlow by late October. It expects record fourth-quarter revenue to drive profitability.
For the nine months ended September 30, 2026, Mannkind reported 27% total revenue growth, a $58.9 million net loss and a $36.9 million, or 73%, increase in commercial product gross profit.
MannKind reported Q3 2026 total revenues of $101.9 million, up 24% from Q3 2025, as commercial product revenue reached $45.0 million. Furoscix ReadyFlow shipments began in mid-September and represented approximately 75% of current weekly Furoscix shipments.
Mannkind said inhaled natetanib is entering phase 2 with about 140 patients testing two doses in about 12 or 13 countries, after initial dosing showed no diarrhea or cough-related discontinuations.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Third-quarter revenue rose 24%, commercial product revenue rose 102%, and ReadyFlow adoption reached approximately 75% of current weekly Furoscix shipments. Management expects Q4 and 2027 profitability, but the company reported a $23.2 million GAAP net loss, lower gross margin, and sharply higher selling, general and administrative expenses.
- + Q3 total revenue increased 24% to $101.9 million new
- + Commercial product revenue increased 102% to $45.0 million new
- + ReadyFlow reached approximately 75% of current weekly Furoscix shipments new
- + Furoscix is expected to generate more fourth-quarter revenue than in the first half of 2026 new
- + Average monthly new-to-brand Afrezza prescriptions increased approximately 80% new
- + Management expects profitability in the fourth quarter and on an annual basis in 2027 new
- − Q3 GAAP net loss was $23.2 million versus $8.0 million of net income in the prior-year quarter new
- − Commercial cost of goods sold increased to $11.2 million and gross margin declined new
- − Selling, general and administrative expenses increased 111% to $61.4 million new
- − Collaboration and services revenue declined 27% new
- − Afrezza's adult business underperformed this year new
- − Pediatric Afrezza prescription growth is running ahead of revenue while paid insurance conversion remains incomplete new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | $96.6M | as of September 30, 2026 | — |
| Non-GAAP adjusted net (loss) income non-GAAP | -10.41M | Nine Months Ended September 30, 2026 | — |
| Pediatric patients treated with Afrezza | 2,000 | since launch | — |
| Share of Furoscix shipments transitioned to ReadyFlow | 75% | by late October | — |
| Integrated Delivery Networks doses purchased increase | 36% | Q2 2026 | — |
| Nephrology units dispensed increase | 67% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNKD
this stock
Mannkind Corp
|
$1.27B | -30.3% | +22.2% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNKD | -5.1% | +23.4% | +11.9% | +12.9% | -30.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +0.4% | +29.7% | +17.5% | +18.1% | -35.3% |